CY1115713T1 - Παραγωγα ακρυλαμιδιου ως αντιβιοτικοι παραγοντες - Google Patents

Παραγωγα ακρυλαμιδιου ως αντιβιοτικοι παραγοντες

Info

Publication number
CY1115713T1
CY1115713T1 CY20141100905T CY141100905T CY1115713T1 CY 1115713 T1 CY1115713 T1 CY 1115713T1 CY 20141100905 T CY20141100905 T CY 20141100905T CY 141100905 T CY141100905 T CY 141100905T CY 1115713 T1 CY1115713 T1 CY 1115713T1
Authority
CY
Cyprus
Prior art keywords
producers
acrylamide
antibiotic agents
antibiotic
agents
Prior art date
Application number
CY20141100905T
Other languages
English (en)
Inventor
Bruce Jeremy Sargent
Henry PAULS
Judd M Berman
Jailall Ramnauth
Peter Sampson
Andras Toro
Fernando J L Martin
Matthew David Surman
Helene Yvonne Decornez
David Douglas Manning
Original Assignee
Debiopharm International Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm International Sa filed Critical Debiopharm International Sa
Publication of CY1115713T1 publication Critical patent/CY1115713T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

Εν μέρει, η παρούσα εφεύρεση απευθύνεται σε αντιβακτηριακές ενώσεις.
CY20141100905T 2004-06-04 2014-10-31 Παραγωγα ακρυλαμιδιου ως αντιβιοτικοι παραγοντες CY1115713T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57694504P 2004-06-04 2004-06-04
EP05858503.5A EP1828167B1 (en) 2004-06-04 2005-06-06 Acrylamide derivatives as antibiotic agents

Publications (1)

Publication Number Publication Date
CY1115713T1 true CY1115713T1 (el) 2017-01-25

Family

ID=37889654

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100905T CY1115713T1 (el) 2004-06-04 2014-10-31 Παραγωγα ακρυλαμιδιου ως αντιβιοτικοι παραγοντες

Country Status (12)

Country Link
US (2) US8450307B2 (el)
EP (2) EP2848614A3 (el)
JP (1) JP5087406B2 (el)
KR (1) KR101299399B1 (el)
CA (1) CA2568914C (el)
CY (1) CY1115713T1 (el)
DK (1) DK1828167T3 (el)
ES (1) ES2515101T3 (el)
PL (1) PL1828167T3 (el)
PT (1) PT1828167E (el)
SI (1) SI1828167T1 (el)
WO (1) WO2007053131A2 (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4803935B2 (ja) * 1999-10-08 2011-10-26 アフィニアム・ファーマシューティカルズ・インコーポレイテッド Ｆａｂｉ阻害剤
DE60230934D1 (de) * 2001-04-06 2009-03-05 Affinium Pharm Inc Fab-i-inhibitoren
WO2008009122A1 (en) 2006-07-20 2008-01-24 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab i inhibitors
EP3255045A1 (en) 2007-02-16 2017-12-13 Debiopharm International SA Salts, prodrugs and polymorphs of fab i inhibitors
EP2224923A4 (en) 2007-11-28 2013-05-15 Sequoia Pharmaceuticals Inc COMPOSITIONS AND METHOD FOR INHIBITING ZYTOCHROM P450 2D6
WO2010089993A1 (ja) 2009-02-03 2010-08-12 クミアイ化学工業株式会社 縮合環化した２－ピリドン誘導体及び除草剤
BR112012011793A2 (pt) 2009-11-18 2019-09-24 Fab Pharma Sas "acrilamidas heterocíclicas e seu uso como farmacêuticos"
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
BR112013011188B1 (pt) 2010-11-05 2022-01-04 Senomyx, Inc Método não-médico para modular canal potencial de receptor transiente de melastina 8 (trpm8), método não-médico para modular a sensação de resfriamento de uma composição, método não-médico para induzir uma sensação de resfriamento em um humano ou animal e composto
HUP1000598A2 (en) 2010-11-05 2012-09-28 Richter Gedeon Nyrt Indole derivatives
CA2842531C (en) * 2011-08-10 2019-07-16 Janssen R&D Ireland Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones
MX360856B (es) * 2011-08-10 2018-11-20 Janssen Sciences Ireland Uc 3,4-dihidro-1h-[1,8]naftiridinosas sustituidas con homopiperidinilo antibacterianas.
JO3611B1 (ar) 2011-08-10 2020-08-27 Janssen Sciences Ireland Uc سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم
EP3330269B1 (en) * 2011-09-19 2023-06-07 Kumar, Ajay Heterocyclic compounds as inhibitors of fatty acid biosynthesis for bacterial infections
LT2861608T (lt) 2012-06-19 2019-07-10 Debiopharm International Sa (e)-n-metil-n-((3-metilbenzofuran-2-il)metil)-3-(7-okso-5,6,7,8-tetrahidro-1,8-nafthidrin-3-il)akrilamido provaisto dariniai
MX367309B (es) * 2012-08-10 2019-08-14 Janssen Sciences Ireland Uc Nuevos compuestos antibacterianos.
WO2014023815A1 (en) * 2012-08-10 2014-02-13 Janssen R&D Ireland New antibacterial compounds
WO2014072930A2 (en) * 2012-11-09 2014-05-15 Aurigene Discovery Technologies Limited Fused pyridine derivatives as antibacterial agents
EP3356356B1 (en) 2015-10-01 2021-05-26 Firmenich Incorporated Compounds useful as modulators of trpm8
HUE052140T2 (hu) 2016-02-26 2021-04-28 Debiopharm Int Sa Diabéteszes lábfertõzések kezelésére szolgáló gyógyszer
US20230035837A1 (en) * 2018-11-12 2023-02-02 Debiopharm International S.A. Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
US10947253B2 (en) 2019-08-05 2021-03-16 Ankh Life Sciences Limited Fused polycyclic dimers
WO2021243273A1 (en) * 2020-05-29 2021-12-02 Taxis Pharmaceuticals, Inc. Bacterial efflux pump inhibitors
CN111991385A (zh) * 2020-08-17 2020-11-27 暨南大学 棕榈油酸在抑制水产病原菌中的应用
WO2022187329A1 (en) * 2021-03-03 2022-09-09 The Board Of Trustees Of The University Of Illinois Fabi inhibitors for gram-negative pathogens

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3828068A (en) 1971-05-10 1974-08-06 Tenneco Chem ((substituted indazolyl)-n1-methyl)carbamates
US4154943A (en) 1977-12-29 1979-05-15 University Of Vermont Preparation of vincadifformine
FR2619111B1 (fr) 1987-08-07 1991-01-11 Synthelabo Derives de (piperidinyl-4)methyl-2 tetrahydro-1,2,3,4 9h-pyrido (3,4-b) indole, leur preparation et leur application en therapeutique
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
BE1003945A3 (fr) * 1990-10-04 1992-07-22 Fina Research Procede de decoloration de polymeres resineux du type vinylaromatique-diene conjugue.
HU210679B (en) 1991-11-21 1995-06-28 Richter Gedeon Vegyeszet Process for producing new tetrahydro-pyrido/3,4-b/indol derivatives and pharmaceutical compositions containing the same
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5416193A (en) 1993-04-30 1995-05-16 Pfizer Inc. Coupling reagent and method
US5614551A (en) 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents
US6176842B1 (en) 1995-03-08 2001-01-23 Ekos Corporation Ultrasound assembly for use with light activated drugs
US5989832A (en) 1995-04-21 1999-11-23 Microcide Pharmaceuticals, Inc. Method for screening for non-tetracycline efflux pump inhibitors
JPH11506429A (ja) 1995-05-11 1999-06-08 ビオヘミー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 抗細菌セファロスポリン類
US6057291A (en) 1995-06-02 2000-05-02 University Of British Columbia Antimicrobial cationic peptides
EP0890359B1 (en) 1996-02-29 2002-05-02 Fujisawa Pharmaceutical Co., Ltd. Tablets containing beta-lactam antibiotic and process for producing the same
US6239154B1 (en) 1996-03-08 2001-05-29 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US6367985B1 (en) 1996-03-12 2002-04-09 Intellectual Property Company Optical connector using large diameter alignment features
US6451816B1 (en) 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
JPH1023696A (ja) * 1996-07-01 1998-01-23 Sankyo Seiki Mfg Co Ltd スピンドルモータおよびその製造方法
US6503881B2 (en) 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6995254B1 (en) 1996-08-28 2006-02-07 Affinium Pharmaceuticals, Inc. Polynucleotide encoding the enoyl-acyl carrier protein reductase of Staphylococcus aureus, FAB I
CZ295199B6 (cs) 1996-09-20 2005-06-15 Meiji Seika Kaisha Ltd. Krystalický pivoxyl cefditoren a způsob jeho výroby
US6521408B1 (en) 1997-09-25 2003-02-18 National Institute Of Agrobiological Sciences Method for assessing a function of a gene
DE19641437A1 (de) 1996-10-08 1998-04-09 Basf Ag 1,3-Bis-(N-lactamyl)propane und deren pharmazeutische und kosmetische Verwendung
DE19652239A1 (de) 1996-12-16 1998-06-18 Bayer Ag Verwendung von 7-(2-Oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-chinolon- und -naphthyridoncarbonsäure-Derivaten zur Therapie von Helicobacter-pylori-Infektionen und den damit assoziierten gastroduodenalen Erkrankungen
SI9600371B (sl) 1996-12-18 2005-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Etilidenski derivati tricikličnih karbapenemov
CA2282593A1 (en) 1997-03-31 1998-10-08 Du Pont Pharmaceuticals Company Indazoles of cyclic ureas useful as hiv protease inhibitors
PT971735E (pt) 1997-04-01 2008-06-02 Borody Thomas J Métodos e composições para tratamento de doença inflamatória do intestino
US6406880B1 (en) 1997-05-02 2002-06-18 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
US6184363B1 (en) 1997-06-13 2001-02-06 Northwestern University Inhibitors of β-lactamases and uses therefor
WO1998058928A1 (fr) 1997-06-23 1998-12-30 Yoshitomi Pharmaceutical Industries, Ltd. Agent prophylactique ou therapeutique contre des maladies attribuables a une infection par des helicobacters
AUPO758297A0 (en) 1997-06-27 1997-07-24 Rowe, James Baber Control of acidic gut syndrome
US6198000B1 (en) 1997-07-07 2001-03-06 Pfizer Inc. Intermediates useful in the synthesis of quinoline antibiotics
EP1000935A4 (en) 1997-07-25 2001-03-21 Tsumura & Co PYRIDYLACRYLAMIDE DERIVATIVES, NEPHRITIS REMEDIES, AND TGF-BETA INHIBITORS CONTAINING THE SAME
HN1998000106A (es) 1997-08-01 1999-01-08 Pfizer Prod Inc Composiciones parenterales de alatroflaxacino
US5932743A (en) 1997-08-21 1999-08-03 American Home Products Corporation Methods for the solid phase synthesis of substituted indole compounds
GB9717804D0 (en) 1997-08-22 1997-10-29 Zeneca Ltd Chemical compounds
US6432444B1 (en) 1997-10-31 2002-08-13 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymes for treating dermatological infections
HUP0001729A3 (en) 1997-10-31 2002-04-29 Syngenta Participations Ag Glyphosate resistant transgenic plants
SE9704404D0 (sv) 1997-11-28 1997-11-28 Astra Ab New compounds
GB9725244D0 (en) 1997-11-29 1998-01-28 Zeneca Ltd Chemical compounds
DE19753298A1 (de) 1997-12-01 1999-06-02 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
PL194097B1 (pl) 1998-01-07 2007-04-30 Meiji Seika Kaisha Kompozycja zawierająca krystalograficznie trwałą amorficzną cefalosporynę i sposób jej wytwarzania
US6184380B1 (en) 1999-01-25 2001-02-06 Pfizer Inc. Process for preparing naphthyridones and intermediates
PA8466701A1 (es) 1998-01-21 2000-09-29 Pfizer Prod Inc Comprimido de mesilato de trovafloxacino
US6204279B1 (en) 1998-06-03 2001-03-20 Microcide Pharmaceuticals, Inc. Peptidomimetic efflux pump inhibitors
PL204797B1 (pl) 1998-02-27 2010-02-26 Straumann Inst Ag Zastosowanie preparatów aktywnej substancji szkliwa
US6350738B1 (en) 1998-03-06 2002-02-26 Brigham Young University Steroid derived antibiotics
DE19820801A1 (de) 1998-05-09 1999-11-25 Gruenenthal Gmbh Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten
DE19821039A1 (de) 1998-05-11 1999-11-18 Bayer Ag Verfahren zur Herstellung von (S,S)-Benzyl-2,8-diazabicyclo[4.3.0]nonan
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
US6428579B1 (en) 1998-07-01 2002-08-06 Brown University Research Foundation Implantable prosthetic devices coated with bioactive molecules
US6423741B1 (en) 1998-07-10 2002-07-23 Council Of Scientific And Industrial Research Anti-microbial composition and method for producing the same
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
CA2339147C (en) 1998-08-04 2009-04-21 Fujisawa Pharmaceutical Co., Ltd. Stabilized preparations of .beta.-lactam antibiotic
DK1025846T3 (da) 1998-08-21 2006-11-06 Kyorin Seiyaku Kk Vandige flydende præparater
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US6518487B1 (en) 1998-09-23 2003-02-11 Pioneer Hi-Bred International, Inc. Cyclin D polynucleotides, polypeptides and uses thereof
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
DE19851104C2 (de) 1998-11-06 2003-04-03 Huhtamaki Forchheim Verfahren zum Herstellen eines mehrschichtigen Verbundes
TW526202B (en) 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
JP4819223B2 (ja) 1999-02-18 2011-11-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 発光マーカーとして使用するためのフタルアミド−ランタニド錯体
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
AU3615200A (en) 1999-03-03 2000-09-21 Princeton University Bacterial transglycosylases: assays for monitoring the activity using lipid ii substrate analogs and methods for discovering new antibiotics
US6495161B1 (en) 1999-03-09 2002-12-17 Vivorx, Inc. Cytoprotective biocompatible containment systems for biologically active materials and methods of making same
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
JP2003502282A (ja) 1999-04-08 2003-01-21 ザ ゼネラル ホスピタル コーポレーション ヒト転移性細胞の作用因子源から離れた意図された移動
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
US6290946B1 (en) 1999-05-13 2001-09-18 Geltex Pharmaceuticals, Inc. Anionic polymers as toxin binders and antibacterial agents
US6514535B2 (en) 1999-05-21 2003-02-04 Noveon Ip Holdings Corp. Bioadhesive hydrogels with functionalized degradable crosslinks
AR024077A1 (es) 1999-05-25 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
AR024158A1 (es) 1999-06-01 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
US6239141B1 (en) 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions
CO5180605A1 (es) 1999-06-23 2002-07-30 Smithkline Beecham Corp Compuestos de indol
CA2282066C (en) 1999-06-29 2010-09-07 Smithkline Beecham Corporation Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6346391B1 (en) 1999-07-22 2002-02-12 Trustees Of Tufts College Methods of reducing microbial resistance to drugs
ATE270558T1 (de) 1999-08-26 2004-07-15 Ganeden Biotech Inc Verwendung von emu-öl als träger für fungizide, antibakterielle und antivirale arzneien
US6221859B1 (en) 1999-08-27 2001-04-24 Merck & Co., Inc. Carbapenem antibacterial compositions and methods of the treatment
US6174878B1 (en) 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
ES2282134T3 (es) 1999-09-11 2007-10-16 THE PROCTER & GAMBLE COMPANY Copolimeros de polioxialquileno que contienen vehiculos liquidos fluidos.
KR20010101030A (ko) 1999-09-17 2001-11-14 도리이 신이찌로 제약학적 항균 조성물
US6500463B1 (en) 1999-10-01 2002-12-31 General Mills, Inc. Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles
JP4803935B2 (ja) * 1999-10-08 2011-10-26 アフィニアム・ファーマシューティカルズ・インコーポレイテッド Ｆａｂｉ阻害剤
US6762201B1 (en) 1999-10-08 2004-07-13 Affinium Pharmaceuticals, Inc. Fab I inhibitors
US6730684B1 (en) 1999-10-08 2004-05-04 Affinium Pharmaceuticals, Inc. Fab I inhibitors
US6503908B1 (en) 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
ES2225237T3 (es) 1999-10-19 2005-03-16 Sato Pharmaceutical Co. Ltd. Agentes antimicrobianos de tipo 4-oxoquinolizina que tienen cadenas principales de 2-piridona como estructura parcial.
US6951729B1 (en) 1999-10-27 2005-10-04 Affinium Pharmaceuticals, Inc. High throughput screening method for biological agents affecting fatty acid biosynthesis
PT1666028E (pt) 1999-10-29 2010-06-15 Novartis Ag Composições de pós anidros com melhor dispersividade
US6531291B1 (en) 1999-11-10 2003-03-11 The Trustees Of Columbia University In The City Of New York Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof
US6514986B2 (en) 2000-11-22 2003-02-04 Wockhardt Limited Chiral fluoroquinolone arginine salt forms
US6372752B1 (en) 2000-02-07 2002-04-16 Genzyme Corporation Inha inhibitors and methods of use thereof
WO2001072317A1 (en) 2000-03-28 2001-10-04 Council Of Scientific And Industrial Research Formulation comprising thymol useful in the treatment of drug resistant bacterial infections
US6448449B2 (en) 2000-04-21 2002-09-10 Rhodia Chirex, Inc. Process for preparation of (R)-1- (aryloxy)propan-2-ol
AU2001282988B2 (en) 2000-07-26 2006-01-05 Atopic Pty Ltd Methods for treating atopic disorders
DE10037029A1 (de) 2000-07-27 2002-02-28 Kugelstrahlzentrum Aachen Gmbh Verfahren und Vorrichtung zum Umformen von Strukturbauteilen
US6288239B1 (en) 2000-09-19 2001-09-11 Board Of Trustees Operating Michigan State University 5-trityloxymethyl-oxazolidinones and process for the preparation thereof
US7048926B2 (en) 2000-10-06 2006-05-23 Affinium Pharmaceuticals, Inc. Methods of agonizing and antagonizing FabK
AU2000277557A1 (en) * 2000-10-06 2002-04-22 Smith Kline Beecham Corporation Methods of agonizing and antagonizing fabk
US6821746B2 (en) 2000-10-06 2004-11-23 Affinium Pharmaceuticals, Inc. Methods of screening for FabK antagonists and agonists
US6388070B1 (en) 2001-01-05 2002-05-14 Orchid Chemicals & Pharmaceuticals Ltd. Thioester derivatives of thiazolyl acetic acid and their use in the preparation of cephalosporin compounds
US6495158B1 (en) 2001-01-19 2002-12-17 Lec Tec Corporation Acne patch
DE60230934D1 (de) 2001-04-06 2009-03-05 Affinium Pharm Inc Fab-i-inhibitoren
US6503906B1 (en) 2002-02-21 2003-01-07 Ren-Jin Lee Method for optimizing ciprofloxacin treatment of anthrax-exposed patients according to the patient's characteristics
ES2518316T3 (es) * 2002-12-06 2014-11-05 Debiopharm International Sa Compuestos heterocíclicos, métodos de fabricación de los mismos y su uso en terapia
WO2004082586A2 (en) * 2003-03-17 2004-09-30 Affinium Pharmaceuticals, Inc. Phamaceutical compositions comprising inhibitors of fab i and further antibiotics
KR20080075027A (ko) 2005-12-05 2008-08-13 아피늄 파마슈티컬스, 인크. Ｆａｂｉ 억제제 및 항박테리아제로서의헤테로시클릴아크릴아미드 화합물
WO2008009122A1 (en) 2006-07-20 2008-01-24 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab i inhibitors
EP3255045A1 (en) 2007-02-16 2017-12-13 Debiopharm International SA Salts, prodrugs and polymorphs of fab i inhibitors
CA2757954A1 (en) 2009-04-08 2010-10-14 C & D Zodiac, Inc. Vehicle seat tubing having variable wall thickness
JP6013846B2 (ja) 2011-10-06 2016-10-25 リコー電子デバイス株式会社 スイッチングレギュレータ及び電子機器
US8975502B1 (en) 2012-05-15 2015-03-10 Rodulfo Delgado Guitar with body-mounted tuning system
US8973902B2 (en) 2012-12-21 2015-03-10 Comeup Industries Inc. Power winch horizontal-pull clutch device

Also Published As

Publication number Publication date
WO2007053131A2 (en) 2007-05-10
US8450307B2 (en) 2013-05-28
EP1828167B1 (en) 2014-08-06
WO2007053131A3 (en) 2007-08-02
KR20080016517A (ko) 2008-02-21
EP2848614A3 (en) 2015-07-29
CA2568914A1 (en) 2005-12-04
EP1828167A2 (en) 2007-09-05
ES2515101T3 (es) 2014-10-29
DK1828167T3 (da) 2014-10-20
US20100093705A1 (en) 2010-04-15
JP5087406B2 (ja) 2012-12-05
JP2008505194A (ja) 2008-02-21
CA2568914C (en) 2013-09-24
EP2848614A2 (en) 2015-03-18
SI1828167T1 (sl) 2014-12-31
KR101299399B1 (ko) 2013-08-22
US20140107106A1 (en) 2014-04-17
PL1828167T3 (pl) 2015-02-27
PT1828167E (pt) 2014-10-08

Similar Documents

Publication Publication Date Title
CY1115713T1 (el) Παραγωγα ακρυλαμιδιου ως αντιβιοτικοι παραγοντες
EA200702643A1 (ru) Антитела, связывающие tweak
AR110313A2 (es) Derivados de tiazol-2-il-pirrolidina
UY3441Q (es) Cepillo de dientes
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
EA200701918A1 (ru) Белок липокалин
NO20082191L (no) Forbindelser
DE602004031372D1 (de) Nachweis von staphylococcus
UY3402Q (es) Diseno de tractor
CY1112467T1 (el) Παραγωγα 1-θειο-d-γλυκιτολης
ATE483000T1 (de) Naphtalin-amidin-imide
ECSP077130A (es) Uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas en el tratamiento de náuseas y vómitos
NO20082298L (no) Kaliumkanalinhibitorer
CO6241120A2 (es) (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS.
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины
ATE417849T1 (de) Pyrazoloä4,3-düpyrimidine
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
SV2006002296A (es) Tratamiento de mastitis ref. bhc041335-sv
UY3450Q (es) Botella
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
DE502008002979D1 (de) Arylsulfonamide mit analgetischer wirkung
UY3457Q (es) Dentifrico
UY3455Q (es) Dentifrico
UY3444Q (es) Dentifrico
UY3461Q (es) Dentifrico